Working… Menu
Trial record 1 of 1 for:    NCT00894634
Previous Study | Return to List | Next Study

Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00894634
Recruitment Status : Completed
First Posted : May 7, 2009
Last Update Posted : October 23, 2020
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer

Tracking Information
First Submitted Date  ICMJE May 5, 2009
First Posted Date  ICMJE May 7, 2009
Last Update Posted Date October 23, 2020
Study Start Date  ICMJE March 21, 2009
Actual Primary Completion Date April 26, 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 6, 2009)
Log transformed values of AUCL and Cmax [ Time Frame: 72 hours ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
Official Title  ICMJE A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents
Brief Summary The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Allergic Reactions
Intervention  ICMJE Drug: Brompheniramine maleate
Study Arms  ICMJE Experimental: Brompheniramine maleate
Brompheniramine maleate oral solution 1 mg/5 mL, single dose
Intervention: Drug: Brompheniramine maleate
Publications * Pathirana S, Jayawardena S, Meeves S, Thompson GA. Brompheniramine and Chlorpheniramine Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. J Clin Pharmacol. 2018 Apr;58(4):494-503. doi: 10.1002/jcph.1037. Epub 2017 Nov 14.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 21, 2020)
Original Estimated Enrollment  ICMJE
 (submitted: May 6, 2009)
Actual Study Completion Date  ICMJE April 26, 2009
Actual Primary Completion Date April 26, 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender
  2. Symptomatic or asymptomatic children/adolescents as follows:

    • A prior diagnosis of allergic rhinitis and either symptomatic or asymptomatic at the time of entry in the study; or * Symptoms of an acute URI; or
    • No symptoms of an acute URI, but at risk for developing an acute URI as evidenced by the following frequency, crowding, and exposure criteria:

      • Frequency: a history of frequent URIs defined as greater than 6 infections/yr for children aged 2 to less than 6 yrs and as greater than 4 infections per year for adolescents aged 6 to less than 18 yrs;
      • Crowding: living in a home with greater than 4 persons, or sleeping in the same bedroom with greater than 3 persons;
      • Exposure: the presence of another family member in the household who is ill with a URI, or a child in the family that is attending preschool, or attending school with greater than 6 children in the class;
  3. Except for allergic rhinitis or a URI, children/adolescents are in normal physical health (i.e., no clinically significant systemic disease) as judged by the Investigator upon physical examination of the subject;
  4. Subjects do not require concomitant medication except for low-dose inhaled glucocorticoids for allergic rhinitis or mild concomitant asthma, if dose is stabilized before entry in the study (i.e., dose is not changed for one month prior to or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed;
  5. Post menarchal females must be using a reliable method of contraception (i.e., oral, transdermal, injectable or implanted contraceptives, IUD, cervical cap, diaphragm, condom, abstinence, or surgical sterility).

Exclusion Criteria:

  1. The child/adolescent weighs less than 24 pounds or is below the 5th or above the 95th percentiles in physical growth characteristics (i.e., height and weight), and BMI based on age and gender;
  2. Inability to swallow the medication;
  3. Eaten within 2 hours prior to dosing;
  4. A known hypersensitivity to BROM, any other antihistamine, or EMLA cream;
  5. Systolic and/or diastolic blood pressure at or above the 95th percentile based on gender, and age and height percentiles. (Note: If a subject with no history of hypertension has a blood pressure reading at or above the 95th percentile, the subject will be allowed to rest for 15 minutes and the blood pressure measurement repeated. Up to 3 consecutive measurements at approximately 5 min intervals will be allowed. Subjects who continue to have systolic and/or diastolic blood pressure readings at or above the 95th percentile will be excluded from the study);
  6. History of melena or any hepatic, renal, endocrine (e.g., diabetes, thyroid disorder), cardiac, neurological, psychiatric, gastrointestinal, hematological or metabolic disorder deemed to be clinically significant by the Investigator;
  7. Any serious medical condition or medical history felt by the Investigator to place them at increased risk;
  8. The child is diagnosed with anemia or has a red blood cell count or hemoglobin level outside of normal range as evidenced by baseline hematology assessment;
  9. Asthma symptoms at the time of entry in the study or requires medication other than allowed under Inclusion Criterion d;
  10. Failure to comply with appropriate washout periods for any H-1 receptor antagonist treatment before and during the study, i.e., no use within 7 days of entering the study or at any time during the study, and no use of astemizole within the preceding 3 calendar months;
  11. Other than described in Exclusion Criterion i, use of any medication 72 hours prior to dosing;
  12. A history of drug, alcohol, or tobacco abuse (older children and adolescents), a history of Hepatitis B, a previous positive test for Hepatitis B surface antigen, or a previous positive Hepatitis C antibody;
  13. A history of HIV infection or previous demonstration of HIV antibodies;
  14. Female subjects who have experienced menarche and have a positive urine pregnancy test;
  15. Parent/guardian/subject judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
  16. Have taken an investigational drug within 30 days prior to entering the study or have already participated in the trial;
  17. Relative of the Sponsor, Investigator, or any personnel of the study site who are directly involved with the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 2 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00894634
Other Study ID Numbers  ICMJE BF-08-06
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth is now a wholly owned subsidiary of Pfizer
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP